{
    "clinical_study": {
        "@rank": "65497", 
        "arm_group": [
            {
                "arm_group_label": "Momelotinib", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive momelotinib plus placebo to match ruxolitinib."
            }, 
            {
                "arm_group_label": "Ruxolitinib", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive ruxolitinib plus placebo to match momelotinib."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib in\n      participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential\n      thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a\n      Janus kinase inhibitor (JAK inhibitor).\n\n      Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a\n      double-blind treatment phase, after which they will be eligible to receive open-label MMB\n      for up to an additional 168 weeks. After discontinuation of study medication, assessments\n      will continue for 12 additional weeks, after which participants will be contacted for\n      survival follow-up approximately every 6 months for up to 5 years from the date of\n      enrollment."
        }, 
        "brief_title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Myelofibrosis", 
            "Post-Polycythemia Vera Myelofibrosis", 
            "Post-Essential Thrombocythemia Myelofibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Palpable splenomegaly at least 5 cm below the left costal margin\n\n          -  Confirmed diagnosis of PMF or post-PV/ET MF\n\n          -  Requires myelofibrosis therapy, in the opinion of the investigator\n\n          -  Classified as high risk OR intermediate-2 risk as defined by the International\n             Prognostic Scoring System (IPSS) for PMF, or intermediate-1 risk (IPSS) associated\n             with symptomatic splenomegaly, hepatomegaly, anemia (hemoglobin < 10.0 g/dL), and/or\n             unresponsive to available therapy\n\n          -  Acceptable laboratory assessment obtained within 14 days prior to the first dose of\n             study drug:\n\n               -  Absolute neutrophil count (ANC) \u2265 0.75 x 10^9/L in the absence of growth factor\n                  in the prior 7 days\n\n               -  Platelet Count \u2265 50 x 10^9/L (\u2265 100 x 10^9/L if aspartate aminotransferase [AST]\n                  or alanine aminotransferase [ALT] is \u2265 2 x the upper limit of the normal range\n                  [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in\n                  the prior 7 days\n\n               -  Peripheral blood blast count < 10%\n\n               -  AST and ALT \u2264 3 x ULN (\u2264 5 x ULN if liver is involved by extramedullary\n                  hematopoiesis as judged by the investigator or if related to iron chelator\n                  therapy that was started within the prior 60 days)\n\n               -  Calculated creatinine clearance (CrCL) of \u2265 45 mL/min\n\n               -  Direct bilirubin \u2264 2.0 x ULN\n\n          -  Life expectancy of > 24 weeks\n\n          -  Males and females of childbearing potential must agree to use protocol-specified\n             method(s) of contraception\n\n          -  Females who are nursing must agree to discontinue nursing before the first dose of\n             study drug\n\n          -  Able to understand and willing to sign the informed consent form\n\n        Exclusion Criteria:\n\n          -  Prior splenectomy\n\n          -  Splenic irradiation within 3 months prior to the first dose of study drug\n\n          -  Eligible for allogeneic bone marrow or stem cell transplantation\n\n          -  Uncontrolled inter-current illness, per protocol.\n\n          -  Known positive status for human immunodeficiency virus (HIV)\n\n          -  Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C\n             carrier\n\n          -  Prior use of a JAK1 or JAK2 inhibitor\n\n          -  Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy,\n             or investigational therapy within 4 weeks of the first dose of study drug\n\n          -  Presence of peripheral neuropathy \u2265 Common Terminology Criteria for Adverse Events\n             (CTCAE) Grade 2\n\n          -  Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed\n             tomography (CT) scan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969838", 
            "org_study_id": "GS-US-352-0101", 
            "secondary_id": "2013-002707-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Momelotinib", 
                "description": "Momelotinib tablet administered orally once daily", 
                "intervention_name": "Momelotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-0387", 
                    "CYT387"
                ]
            }, 
            {
                "arm_group_label": "Ruxolitinib", 
                "description": "Ruxolitinib tablets administered orally twice daily", 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ruxolitinib", 
                "description": "Placebo to match momelotinib tablets administered orally once daily", 
                "intervention_name": "Placebo to match momelotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Momelotinib", 
                "description": "Placebo to match ruxolitinib tablets administered orally twice daily", 
                "intervention_name": "Placebo to match ruxolitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Escondido", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pleasant Hill", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tupelo", 
                        "country": "United States", 
                        "state": "Mississippi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Missoula", 
                        "country": "United States", 
                        "state": "Montana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", 
        "overall_contact": {
            "email": "momelotinib.studies@gilead.com", 
            "last_name": "Clinical Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Peter Lee, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Canada: Health Canada", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Singapore: Health Sciences Authority", 
                "Taiwan : Food and Drug Administration", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Splenic response rate at Week 24 is defined as the proportion of participants achieving a \u2265 35% reduction in spleen volume at Week 24 from baseline as measured by MRI or CT.", 
            "measure": "Splenic response rate at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969838"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total symptom score (TSS) is defined as the proportion of participants who achieve a \u2265 50% reduction in TSS from baseline to Week 24 as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) v2.0 diary.", 
                "measure": "Response rate in total symptom score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Rate of RBC transfusion is defined as the average number of RBC units per participant per month.", 
                "measure": "Rate of red blood cell (RBC) transfusion through Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "description": "RBC transfusion independence is the proportion of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the prior 12 weeks.", 
                "measure": "RBC transfusion independence rate at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "RBC transfusion dependence is the proportion of participants who are transfusion dependent at Week 24, defined as at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in the prior 8 weeks.", 
                "measure": "RBC transfusion dependence rate at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}